{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:01:40Z","timestamp":1777741300175,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404760"],"award-info":[{"award-number":["82404760"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404747"],"award-info":[{"award-number":["82404747"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xphs.2025.103906","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:28:02Z","timestamp":1752571682000},"page":"103906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative characterization of drug metabolism and transport alterations in obesity with metabolic fatty liver disease: A physiologically based pharmacokinetic modelling approach"],"prefix":"10.1016","volume":"114","author":[{"given":"Yuewu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaozhuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-0380","authenticated-orcid":false,"given":"Yujie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.103906_bib0001","first-page":"1673","volume":"24","author":"Shafiee","year":"2024"},{"issue":"2","key":"10.1016\/j.xphs.2025.103906_bib0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41575-022-00717-4","article-title":"NAFLD, MAFLD and obesity: brothers in arms?","volume":"20","author":"Machado","year":"2023","journal-title":"Nat Rev Gastro Hepat"},{"issue":"3","key":"10.1016\/j.xphs.2025.103906_bib0003","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.xphs.2025.103906_bib0004","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.xphs.2025.103906_bib0005","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in Human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2025.103906_bib0006","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.xphs.2025.103906_bib0007","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1007\/s00125-024-06260-y","article-title":"An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models","volume":"67","author":"Toma","year":"2024","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.xphs.2025.103906_bib0008","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1007\/s00125-018-4735-7","article-title":"Genome-wide profiling of histone H3K27 acetylation featured fatty acid signalling in pancreatic beta cells in diet-induced obesity in mice","volume":"61","author":"Nammo","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.xphs.2025.103906_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48746-5","article-title":"Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease","volume":"9","author":"Hoang","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xphs.2025.103906_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12967-020-02540-4","article-title":"Credible practice of modeling and simulation in healthcare: ten rules from a multidisciplinary perspective","volume":"18","author":"Erdemir","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.xphs.2025.103906_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based Pharmacokinetic Modeling in regulatory science: an update from the U.S. Food and Drug Administration's Office of Clinical Pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci-Us"},{"key":"10.1016\/j.xphs.2025.103906_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13742-015-0089-y","article-title":"Rcorrector: efficient and accurate error correction for Illumina RNA-seq reads","volume":"4","author":"Song","year":"2015","journal-title":"Gigascience"},{"issue":"10","key":"10.1016\/j.xphs.2025.103906_bib0013","first-page":"647","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole clarithromycin midazolam alfentanil digoxin, CPT pharmacomet","volume":"7","author":"Hanke","year":"2018","journal-title":"Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103906_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030331","article-title":"Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network","volume":"13","author":"Marok","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.xphs.2025.103906_bib0015","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","article-title":"Physiologically based pharmacokinetic modeling of Rosuvastatin to predict transporter-mediated drug-drug interactions","volume":"38","author":"Hanke","year":"2021","journal-title":"Pharm Res-Dordr"},{"issue":"14","key":"10.1016\/j.xphs.2025.103906_bib0016","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2174\/1389200224666230130093314","article-title":"Physiologically-based pharmacokinetic modeling of tenofovir disoproxil fumarate in pregnant women","volume":"23","author":"Zhang","year":"2023","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.xphs.2025.103906_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.xphs.2025.103906_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090222","article-title":"Nonalcoholic fatty liver disease (NAFLD) and hepatic cytochrome P450 (CYP) enzymes","volume":"13","author":"Jamwal","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.xphs.2025.103906_bib0019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cpt.2614","article-title":"Considerations for physiologically based modeling in liver disease: from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH)","volume":"113","author":"Murphy","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.103906_bib0020","doi-asserted-by":"crossref","unstructured":"Gofton, C., et al., MAFLD: how is it different from NAFLD? Clin mol hepatol, 2023. 29(Suppl): S17\u2013s31.","DOI":"10.3350\/cmh.2022.0367"},{"key":"10.1016\/j.xphs.2025.103906_bib0021","unstructured":"Research, U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a., <FDA nonalcoholic steatohepatitis with compensated cirrhosis developing drugs for treatment guidance for industry.Pdf>. 2019."},{"issue":"10","key":"10.1016\/j.xphs.2025.103906_bib0022","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A Activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.xphs.2025.103906_bib0023","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/apt.12046","article-title":"Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?","volume":"36","author":"Yilmaz","year":"2012","journal-title":"Aliment Pharm Ther."},{"issue":"8","key":"10.1016\/j.xphs.2025.103906_bib0024","doi-asserted-by":"crossref","first-page":"e2317","DOI":"10.1002\/brb3.2317","article-title":"High risk of drug toxicity in social isolation stress due to liver dysfunction: role of oxidative stress and inflammation","volume":"11","author":"Zahir","year":"2021","journal-title":"Brain Behav"},{"issue":"12","key":"10.1016\/j.xphs.2025.103906_bib0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/11594420-000000000-00000","article-title":"Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance","volume":"50","author":"Ghobadi","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.xphs.2025.103906_bib0026","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.xphs.2025.103906_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.redox.2014.09.004","article-title":"Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling","volume":"3","author":"Schattenberg","year":"2014","journal-title":"Redox Biol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:28:49Z","timestamp":1777462129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925003582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022354925003582"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103906","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative characterization of drug metabolism and transport alterations in obesity with metabolic fatty liver disease: A physiologically based pharmacokinetic modelling approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103906"}}